Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs LYFT Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while LYFT Inc trades at $15.61 (market cap $5.95B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.
| BIO | LYFT | |
|---|---|---|
Market Cap | $8.02B | $5.95B |
Sector | Health | Industrials |
52-Week High | $339.75 | $24.57 |
52-Week Low | $241.71 | $12.65 |
Enterprise Value | $7.84B | $5.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lyft trades at $15.67, up 0.38% today, with a bullish technical signal and positive cash flow trends. The stock shows attractive valuation metrics with P/E of 2.29 and P/S of 0.99, while recent earnings have been mixed with Q4 2025 beating expectations but Q1 2026 missing. Revenue growth continues with $6.32B in 2025, and the company maintains strong profitability with 43.82% net income margin. Analyst consensus is mixed with 37% buy ratings and $17.86 price target.
Lyft presents a compelling value opportunity with deep valuation discounts and improving fundamentals, though execution risks remain. The company's transition to profitability and strategic expansion into autonomous vehicles provide growth catalysts, but competitive pressures and earnings volatility require careful monitoring. The stock offers 14% upside to consensus target with manageable downside risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
